Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Non-small Cell Lung Cancer Metastatic × olaparib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 79 Breast Neoplasms 55 Prostatic Neoplasms 29 Neoplasms 23 Triple Negative Breast Neoplasms 22 Fallopian Tube Neoplasms 21 Endometrial Neoplasms 17 Pancreatic Neoplasms 16 Neoplasm Metastasis 15 Small Cell Lung Carcinoma 13 Carcinoma, Ovarian Epithelial 10 Stomach Neoplasms 8 Squamous Cell Carcinoma of Head and Neck 8 Sarcoma 8 Carcinoma, Non-Small-Cell Lung 8 Recurrence 7 Glioma 7 Lung Neoplasms 6 Fanconi Anemia, Complementation Group D1 6 Colorectal Neoplasms 6 Lymphoma, Non-Hodgkin 5 Glioblastoma 5 Cholangiocarcinoma 5 Urinary Bladder Neoplasms 4 Solid Tumors 4 Parkinson Disease 4, Autosomal Dominant Lewy Body 4 Neuroendocrine Tumors 4 Metastatic Castration-resistant Prostate Cancer 4 Advanced Solid Tumors 4 Advanced Breast Cancer 4

Interventions

pembrolizumab 3 Bevacizumab 3 tusamitamab ravtansine 2 Ramucirumab 2 Pemetrexed 2 Gemcitabine 2 Erlotinib Hydrochloride 2 Docetaxel 2 Carboplatin 2 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 2 vistusertib 1 vandetanib 1 telomerase reverse transcriptase p572Y, human 1 spartalizumab 1 sotorasib 1 olaparib 1 necitumumab 1 icotinib 1 durvalumab 1 dacomitinib 1 capivasertib 1 aumolertinib 1 Vinorelbine 1 Radiosurgery 1 Platinum 1 Paclitaxel 1 MLN 8237 1 LY3023414 1 Injections 1 GC Temporary Stopping 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02117167 2024-01-10

SAFIR02_Lung

UNICANCER

Phase 2 Completed

Non-small Cell Lung Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡